News
AMRN
0.5923
-4.96%
-0.0309
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
NASDAQ · 1d ago
Weekly Report: what happened at AMRN last week (1028-1101)?
Weekly Report · 3d ago
Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boosts Sales
NASDAQ · 5d ago
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
NASDAQ · 5d ago
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
NASDAQ · 6d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 6d ago
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
NASDAQ · 10/31 13:32
Amarin Corporation: Q3 Highlights and Future Outlook
TipRanks · 10/31 04:26
Based on the provided financial report, the title of the article is: "Amarin Corporation plc Quarterly Report (Form 10-Q)
Press release · 10/31 03:10
AMARIN CORP : QTRLY NON-GAAP ADJUSTED BASIC AND DILUTED LOSS PER SHARE OF $0.05
Reuters · 10/30 20:56
Amarin sees current cash, investments, other assets to support operations
TipRanks · 10/30 20:50
Amarin Non-GAAP EPS of -$0.05 beats by $0.01, revenue of $42.3M misses by $2.21M
Seeking Alpha · 10/30 20:13
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/30 14:50
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
NASDAQ · 10/30 14:07
Here are the major earnings after the close today
Seeking Alpha · 10/30 14:00
Amarin Q3 2024 Earnings Preview
Seeking Alpha · 10/29 21:20
Weekly Report: what happened at AMRN last week (1021-1025)?
Weekly Report · 10/28 09:50
Weekly Report: what happened at AMRN last week (1014-1018)?
Weekly Report · 10/21 09:49
Weekly Report: what happened at AMRN last week (1007-1011)?
Weekly Report · 10/14 09:59
Optimi Health appoints Parisa Zamiri as CMO, Tom Reilly as CFO
TipRanks · 10/08 11:15
More
Webull provides a variety of real-time AMRN stock news. You can receive the latest news about Amarin through multiple platforms. This information may help you make smarter investment decisions.
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.